Barriers and Facilitators to Intracerebral Haemorrhage Platform Trial Recruitment: A Survey of Stroke Clinicians
Rattachement africain : gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Platform trials are an efficient trial design which enables testing of multiple interventions simultaneously. They could advance knowledge of treatments for intracerebral haemorrhage (ICH). We aimed to investigate the views of clinicians involved in stroke research on recruitment to a future platform trial for ICH. METHODS: Between April and July 2025, we conducted a UK-wide online survey of clinicians actively involved in stroke research using convenience sampling through professional organisations. Participants considered factors related to the consent process and research environment and could provide optional free text responses about additional barriers or facilitators to recruitment. We used descriptive statistics for quantitative data and content analysis for qualitative data. RESULTS: Among 73 respondents, 46 (63%) were female, 36 (49%) were stroke physicians, 24 (33%) nurses, 6 (8%) allied health professionals, and 7 (10%) were in other roles. A total of 35 (48%) had >20 years' clinical experience, 44 (60%) reported spending <10% of their role in research. 66 (90%) thought that a platform trial would be a good option for testing interventions for patients with stroke due to ICH. Across 11 modifiable factors, clinicians most frequently rated the perceived importance of the research question and a research-positive culture in the clinical team as facilitators of recruitment (both 92%), while clinician preference for specific treatments was most frequently rated as a barrier (48%). Two themes emerged from free text responses: study design and infrastructure. Regarding study design, respondents perceived consent procedures (n = 9), study materials (n = 8), study procedures (n = 8), eligibility assessment (n = 6), the research question (n = 3), and randomisation (n = 3) as important for a future platform trial. Regarding infrastructure, emergent factors were staffing (n = 17), local research culture and capacity (n = 9), research governance and delivery (n = 6), and training (n = 6). CONCLUSION: The overwhelming majority of respondents from the UK clinical stroke community supported a platform trial for ICH, although the influence of survey responder bias is unknown.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Barriers and Facilitators to Intracerebral Haemorrhage Platform Trial Recruitment: A Survey of Stroke Clinicians
- Date Crossref
- 07/07/2026
- Éditeur
- S. Karger AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Edinburgh Institute for Neuroscience and Cardiovascular Research pays non établi dans la noticeUniversité ou école supérieure
-
University of Nottingham Nottingham Stroke Trials Unit pays non établi dans la noticeUniversité ou école supérieure
-
Monklands Hospital pays non établi dans la noticeÉtablissement de santé
-
Manchester Academic Health Science Centre pays non établi dans la noticeÉtablissement de santé
-
University of Manchester Geoffrey Jefferson Brain Research Centre pays non établi dans la noticeUniversité ou école supérieure
-
Northern Care Alliance NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
UCL Queen Square Institute of Neurology pays non établi dans la noticeUniversité ou école supérieure
-
University College London Stroke Research Centre pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Monklands Department of Stroke Care pays non établi dans la noticeUniversité ou école supérieure
Institute for Neuroscience and Cardiovascular Research — University of Edinburgh, Nottingham Stroke Trials Unit — University of Nottingham et Monklands Hospital, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.